Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Arctic Bioscience AS ( (DE:9TD) ) is now available.
Arctic Bioscience reported its strongest-ever first quarter, with 2026 sales revenues rising 78% year-on-year to NOK 11.9 million and gross margin improving to 34.3% as U.S. nutra sales led growth and adjusted EBITDA loss narrowed. Despite low quarter-end cash of NOK 0.3 million, liquidity has been shored up through NOK 15 million in new long-term financing and an expanded credit facility, supporting continued international expansion of its nutraceutical business.
Operationally, the company highlighted solid order intake and a promising order outlook for 2026, especially in international markets, underlining expectations of further revenue growth. In pharma, Arctic Bioscience reported positive partnering discussions for its psoriasis candidate HRO350 after BIO Europe, with next steps including data publication, phase III design and EMA scientific advice, moves that could de-risk the asset and underpin future partnership or project-based financing.
Arctic Bioscience is also preparing to publish data from the HeROPA psoriasis study and glaucoma research, while designing preclinical studies for brain development in extremely preterm infants. Management and the board continue to monitor liquidity closely and signal that additional financing measures and partnership structures may be pursued to fund further development of its pharma portfolio without overburdening the balance sheet.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical products and dietary supplements based on bioactive marine raw materials. Its pipeline includes HRO350, an oral drug candidate for mild-to-moderate psoriasis, while its ROMEGA-branded marine-based dietary supplements are sold globally as bulk ingredients and finished consumer products.
Average Trading Volume: 16,828
Current Market Cap: NOK93M
See more insights into 9TD stock on TipRanks’ Stock Analysis page.